Rene Bernards
17Patents
3h-index
22Co-inventors
60Inventor score
Filing activity: Jun 7, 1995 → Sep 8, 2016
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7171311B2 | Methods of assigning treatment to breast cancer patients | Chemistry; Metallurgy | 182 | Expired |
| US7514209B2 | Diagnosis and prognosis of breast cancer patients | Emerging Cross-Sectional Technologies | 104 | Expired |
| US6699475B1 | Recombinant pox virus for immunization against tumor-associated antigens | Chemistry; Metallurgy | 15 | Expired |
| US7863001B2 | Diagnosis and prognosis of breast cancer patients | Emerging Cross-Sectional Technologies | 3 | Active |
| US6045999A | Transcription factor E2F-4 | Human Necessities | 2 | Expired |
| US6303335A | Transcription factor E2F-4 | Human Necessities | 2 | Expired |
| US6350572B1 | Interaction between cyclin D1 and steroid receptor coactivators and users thereof in assays | Physics | 1 | Expired |
| US7928081B2 | Combined use of PRAME inhibitors and HDAC inhibitors | Chemistry; Metallurgy | 1 | Expired |
| US8969544B2 | Combined use of PRAME inhibitors and HDAC inhibitors | Chemistry; Metallurgy | 1 | Active |
| US6368809B1 | E2F ubiquitination domain, and assays for inhibitors and enhancers of E2F ubiquitination | Chemistry; Metallurgy | 1 | Expired |
| US6448376B1 | Transcription factor-E2F-5 | Human Necessities | 0 | Expired |
| US5985283A | Adenovirus E1A-Associated protein BS69, inhibitor of E1A-transactivation | Chemistry; Metallurgy | 0 | Expired |
| US6033843A | Interaction of cyclin D1 and estrogen receptor and its use in assays | Physics | 0 | Expired |
| US10864179B2 | Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma | Human Necessities | 0 | Active |
| US7012128B2 | Interaction between cyclin D1 and steroid receptor co-activators and uses thereof in assays | Physics | 0 | Expired |
| US9909185B2 | Diagnosis and prognosis of breast cancer patients | Emerging Cross-Sectional Technologies | 0 | Active |
| US10398696B2 | Combinations for treatment of cancer | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.